Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Leadership Companies Market Intelligence

Titans Of Pharma: Pfizer’s Bourla Tops Big Pharma CEO Compensation League

Bourla’s Total Package Exceeds $30m

  • Data

Executive Summary

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

You may also be interested in...



Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a look at global executive compensation; Pfizer’s new myeloma approval; Merck & Co. and Kelun trump ADC breast cancer success; combo Alzheimer’s therapies in Eisai’s pipeline; and a look at the state of gene therapy.

Pfizer Cost Improvement Program Depends On COVID Outlook

If COVID-19 product sales don’t meet assumptions this fall, the company said it will consider a cost reduction program to better align costs with future revenue projections.

Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

Table

View full table

Topics

Related Companies

Tags:
Leadership Companies Market Intelligence
Latest Headlines

Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18

Amicus Piggybacks Off Galafold Commercial Infrastructure For Pombiliti + Opfolda Launch

Structure Emerges In Obesity Race With Oral GLP-1 Agonist

ViiV In It For The Long Haul In HIV Market Battle With Gilead

See All
UsernamePublicRestriction

Register

SC148887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By